Abstract
Background: Sarcomas are rare malignant tumours of mesenchymal origin that primarily affect connective tissues and bones. Liposarcoma and leiomyosarcoma are the two most common subtypes of soft tissue sarcomas (STS), whereas osteosarcoma is the most common type of bone sarcoma (BS). Clinical utilisation of liquid biopsy may offer a new translational diagnostic and monitoring tool for sarcoma.
Material and methods: We performed a systematic review to evaluate the clinical utility of liquid biopsy in sarcoma. The review was conducted in accordance with the PRISMA guidelines. The review was registered with the International Prospective Register of Systematic Reviews (PROSPERO) (Registration No. CRD42024540626). Relevant literature was searched from all electronic databases MEDLINE via PubMed, EMBASE, Scopus, and the Web of Sciences, and data extraction was performed systematically using Covidence. Meta-analysis was performed on studies reporting survival outcomes [(overall survival (OS), disease-free survival (DFS) or relapse-free survival (RFS), and progression-free survival)]. Either fixed or random effects models were used, taking into consideration heterogeneity. Publication bias was detected using a funnel plot.
Results (For Surgical Trial Proposals fill in ‘the Feasibility’, for Surgical Trial in Progress fill in the ‘Current status’): Nine studies were included in this meta-analysis. Copy number variation is a common mutation detected in both liposarcoma and leiomyosarcoma. Circulating cell-free DNA (cfDNA) can be detected using quantitative PCR (qPCR), droplet digital PCR (ddPCR), and next-generation sequencing. Three studies reported survival outcomes. Generally, in sarcoma, detectable (or positive) cfDNA (or specifically ctDNA) is associated with poorer overall survival (pooled HR, 1.91; 95% CI, 1.37 – 2.68; p = 0.0002) and disease-free survival (HR 2.23; 95% CI 1.27 - 3.90; p = 0.005). The progression-free survival of patients with detectable cfDNA was not significantly different from those without cfDNA (HR 1.13, 95% CI 0.72 – 1.78; p = 0.60). No evidence of publication bias was detected in this study.
Conclusions (For Surgical Trial in Progress and Surgical Trial Proposals f ill in ‘NA’): The findings of this study provide the foundation for future studies that will examine the use of cfDNA in assessing the prognosis and monitoring the relapse of sarcoma.
Material and methods: We performed a systematic review to evaluate the clinical utility of liquid biopsy in sarcoma. The review was conducted in accordance with the PRISMA guidelines. The review was registered with the International Prospective Register of Systematic Reviews (PROSPERO) (Registration No. CRD42024540626). Relevant literature was searched from all electronic databases MEDLINE via PubMed, EMBASE, Scopus, and the Web of Sciences, and data extraction was performed systematically using Covidence. Meta-analysis was performed on studies reporting survival outcomes [(overall survival (OS), disease-free survival (DFS) or relapse-free survival (RFS), and progression-free survival)]. Either fixed or random effects models were used, taking into consideration heterogeneity. Publication bias was detected using a funnel plot.
Results (For Surgical Trial Proposals fill in ‘the Feasibility’, for Surgical Trial in Progress fill in the ‘Current status’): Nine studies were included in this meta-analysis. Copy number variation is a common mutation detected in both liposarcoma and leiomyosarcoma. Circulating cell-free DNA (cfDNA) can be detected using quantitative PCR (qPCR), droplet digital PCR (ddPCR), and next-generation sequencing. Three studies reported survival outcomes. Generally, in sarcoma, detectable (or positive) cfDNA (or specifically ctDNA) is associated with poorer overall survival (pooled HR, 1.91; 95% CI, 1.37 – 2.68; p = 0.0002) and disease-free survival (HR 2.23; 95% CI 1.27 - 3.90; p = 0.005). The progression-free survival of patients with detectable cfDNA was not significantly different from those without cfDNA (HR 1.13, 95% CI 0.72 – 1.78; p = 0.60). No evidence of publication bias was detected in this study.
Conclusions (For Surgical Trial in Progress and Surgical Trial Proposals f ill in ‘NA’): The findings of this study provide the foundation for future studies that will examine the use of cfDNA in assessing the prognosis and monitoring the relapse of sarcoma.
| Original language | English |
|---|---|
| Article number | 109238 |
| Pages (from-to) | 142-142 |
| Number of pages | 1 |
| Journal | European Journal of Surgical Oncology |
| Volume | 50 |
| Issue number | Supplement 2 |
| DOIs | |
| Publication status | Published - 18 Dec 2024 |
| Event | 43th Congress of the European Society of Surgical Oncology - Antwerp, Belgium Duration: 2 Oct 2024 → 4 Oct 2024 Conference number: 43 |